Phosphate-buffered solution, pH 7.2, containing no preservative. 0.2 μm filter sterilized. Endotoxin level is < 0.1 EU/μg of the protein (< 0.01 ng/μg of the protein) as determined by the LAL test.
Preparation:
The antibody was purified by affinity chromatography.
Concentration:
1 mg/ml
Storage & Handling:
The antibody solution should be stored undiluted at 4 °C. This LEAF™ solution contains no preservative; handle under aseptic conditions.
Application:
ELISA Capture1-3 - Quality Tested ELISPOT Capture4-6*, Neutralization1*, ICFC7*, IHC8,9*, WB * - *This application has been reported in the literature.
Recommended Usage:
Each lot of this antibody is quality control tested by ELISA assay. For use as an ELISPOT capture antibody, a concentration range of 4-8 μg/ml is recommended. For ELISA capture applications, a concentration range of 1-4 μg/ml is recommended. To obtain a linear standard curve, serial dilutions of IL-5 recombinant protein ranging from 500 to 4 pg/ml are recommended for each ELISA plate. It is recommended that the reagent be titrated for optimal performance for each application.
Application Notes:
ELISA1-3 or ELISPOT4-6 Capture: The purified JES1-39D10 antibody is useful as the capture antibody in a sandwich ELISA or ELISPOT, when used in conjunction with the biotinylated JES1-5A10 (Cat. No. 501002/501005) antibody as the detecting antibody. The LEAF™ purified antibody is suggested for ELISPOT capture. Flow Cytometry7: The fluorochrome-labelled JES1-39D10 antibody is useful for intracellular immunofluorescent staining and flow cytometric analysis to identify IL-5 -producing cells within mixed cell populations. View intracellular cytokine staining protocol Neutralization1: The LEAF™ purified antibody (Endotoxin <0.1 EU/μg, Azide-Free, 0.2 μm sterile-filtered) is recommended for neutralization of human IL-4 bioactivity (Cat. No. 500907). Additional reported applications (for the relevant formats) include: Western blotting, immunohistochemical staining8,9 of paraformaldehyde-fixed, saponin-treated frozen tissue sections, and immunocytochemistry. Note: For testing human IL-5 in serum or plasma, BioLegend's ELISA Max™ Sets (Cat. No. 430401 to 430406) are specially developed and recommended.
Application References:
1. Abrams, J., et al., 1992. Immunol. Rev. 127: 5. 2. Butterfield, J., et al., 1992. Blood 79: 688. 3. Abrams, J., et al., 1994. Eosinophils in Allergy and Inflammation. Marcel Dekker, New York. p.133. 4. Klinman, D., et al., 1994. Curr. Prot. Immunol.. John Wiley and Sons, New York. Unit 6.19.6. 5. Mahanty, S., et al., 1992. J. Immunol. 148: 3567. 6. Limaye, A., et al., 1991. J. Clin. Inv. 88: 1418. 7. Prussin, C., et al., 1995. J. Immunol. Meth. 188: 117. 8. Andersson, U., et al., 1999. Detection and quantification of gene expression. New York: Springer-Verlag. 9. Andersson, J., et al., 1994. Immunology 83: 16.
Description:
IL-5 is a homodimeric, disulphide-linked protein produced by T-cells. Monomeric human IL-5 is a 126 amino acid protein with a reported molecular weight of 26 kD for the homodimeric protein. Mouse and human IL-5 are approximately 70% identical. IL-5 has been shown to promote the growth of immature hematopoietic BFU-E progenitors, stimulate the activation and differentiation of eosinophils, and promote the generation of cytotoxic lymphocytes. The JES1-39D10 antibody can neutralize the bioactivity of natural or recombinant IL-5.
Other Names:
Interleukin-5, Eosinophil differentiation factor (EDF), Eosinophil colony stimulating factor (Eo-CSF), B cell growth factor-2 (BCGF-2), B cell differentiation factor for IgM (BCDF-m), IgA enhancing factor (IgA-EF), T cell replacing factor-1 (TRF-1)
Structure:
Cytokine; dimer; 45 kD (Mammalian)
Regulation:
Upregulated by IL-2, platelet activating factor; downregulated by TGF-β
Cellular Sources:
Mast cells, T cells, bone marrow stromal cells
Cellular Targets:
Eosinophils
Receptors:
Heterodimer IL-5Rα (CD125); β-subunit (CDw131) in common with IL-3R, GM-CSFR
Bioactivity/Activities:
Growth/differentiation of eosinophils; proliferation/cell activation/differentiation of eosinophilic granulocytes
Antigen References:
1. Fitzgerald, K., et al., Eds. 2001. The Cytokine FactsBook. Academic Press, San Diego. 2. Takatsu, K., et al., 1988. Immunol. Rev. 102:107. 3. Takatsu, K. 1992. Curr. Opin. Immunol. 4:299. 4. Takatsu, K. 1991. Microbiol. Immun. 35:593.
